Trial Profile

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecirasib (Primary) ; Sitneprotafib (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Registrational
Sponsors Allist Pharmaceuticals; Jacobio Pharmaceuticals

12 Mar 2025 Planned number of patients changed from 124 to 240.
04 Jun 2024 Results(As of December 1st, 2023, n=179 pts) safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) ,presented at the 60th Annual Meeting of the American Society of Clinical Oncology
02 Jun 2024 According to a Jacobio Pharmaceuticals media release, about 102 frontline NSCLC patients have been enrolled in 7 dose groups.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com